ReviewNature reviews. Molecular cell biology2026
Mechanisms, functions and therapeutic targeting of protein tyrosine phosphatases.
Review in Nature reviews. Molecular cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The role of classical protein tyrosine phosphatases in diabetic kidney disease and therapeutic implications.Journal of biomedical science · 2026Review
- Molecular Mechanisms and Targeted Therapies of PTPN2 in Metabolic Diseases: A Review.Biomolecules · 2026Review
- Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B.The Journal of biological chemistry · 2026Article
- Article
- Article
- Rational design of a protein-protein interaction inhibitor that activates Protein Tyrosine Phosphatase 1B.bioRxiv : the preprint server for biology · 2026Article
- Phosphatase Signaling as a Therapeutic Strategy in Schizophrenia.International journal of molecular sciences · 2026Review
- Mapping of PTP1B, TCPTP, SHP2, and Putative Substrates Reveals Novel Networks in Glomerular Podocytes.Journal of cellular physiology · 2026Article
- HIT101308137 and HIT104293658 nominate dual target chemotypes for PTPN1 and PTPN2 with preliminary selectivity in colorectal cancer cells.Frontiers in chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrations in protein tyrosine phosphorylation-dependent cell signalling contribute to a wide variety of human diseases. Drugs targeting protein tyrosine kinases have had a major impact on human health; by contrast, protein tyrosine phosphatases (PTPs), which serve unique functions and together with protein tyrosine kinases coordinate tyrosine phosphorylation-dependent cell signalling, have been underexploited therapeutically. In this Review, we discuss key breakthroughs in our understanding of how PTPs are regulated, highlight their capacity to coordinate signalling and provide examples of their complex roles in physiology and pathophysiology, including diabetes, obesity and cancer. Also, we discuss the development of PTP-targeted therapeutics that are in clinical trials or poised for clinical translation. We argue that the emergence of this class of enzymes from the shadows lays the foundation for a more complete understanding of the regulation of cell signalling and heralds a new era of drug development opportunities to combat important human diseases.
Indexed as
Identifiers
41028199What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.